Alx Oncology Holdings (ALXO) Change in Account Payables (2019 - 2026)
Alx Oncology Holdings recorded quarterly Change in Account Payables of -$1.2 million in Q1 2026, up 27.5% quarter-over-quarter from -$1.7 million in Q4 2025, and down 117.63% year-over-year from $6.9 million in Q1 2025.
Alx Oncology Holdings' Change in Account Payables history runs 8 years deep, the most recent figure standing at -$1.2 million for Q1 2026.
- In Q1 2026, Change in Account Payables fell 117.63% year-over-year to -$1.2 million; the TTM figure through Mar 2026 stood at -$233000.0 (up 89.66% YoY), while the FY2025 annual figure was $421000.0, up 110.46% from the prior year.
- Change in Account Payables came in at -$1.2 million for Q1 2026 at Alx Oncology Holdings, up from -$1.7 million in the prior quarter.
- In the past five years, Change in Account Payables ranged from a high of $8.9 million in Q3 2023 to a low of -$5.7 million in Q2 2023.
- A 5-year average of $8882.4 and a median of -$194000.0 in 2024 frame the typical range for Change in Account Payables.
- Across the five-year window, Change in Account Payables slumped 282.72% in 2023 and soared 966.49% in 2025, its largest moves.
- Alx Oncology Holdings' Change in Account Payables stood at $2.5 million in 2022, then plunged by 282.72% to -$4.5 million in 2023, then climbed by 24.46% to -$3.4 million in 2024, then jumped by 50.72% to -$1.7 million in 2025, then grew by 27.5% to -$1.2 million in 2026.
- According to Business Quant data, Change in Account Payables over the past three periods registered -$1.2 million, -$1.7 million, and $1.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -3.26 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 35.60 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Alx Oncology Holdings | 189.80 Mn | 49.48 Mn | - | -1.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.21 Mn |
| Mar 31, 2026 | -1.21 Mn |
| Dec 31, 2025 | -1.67 Mn |
| Dec 31, 2025 | -1.67 Mn |
| Sep 30, 2025 | 1.68 Mn |
| Sep 30, 2025 | 1.68 Mn |
| Jun 30, 2025 | 965,000.00 |
| Jun 30, 2025 | 965,000.00 |
| Mar 31, 2025 | -556,000.00 |
| Mar 31, 2025 | -556,000.00 |
| Dec 31, 2024 | -3.39 Mn |
| Dec 31, 2024 | -3.39 Mn |
| Sep 30, 2024 | -194,000.00 |
| Sep 30, 2024 | -194,000.00 |
| Jun 30, 2024 | 1.88 Mn |
| Jun 30, 2024 | 1.88 Mn |
| Mar 31, 2024 | -2.33 Mn |
| Mar 31, 2024 | -2.33 Mn |
| Dec 31, 2023 | -4.48 Mn |
| Dec 31, 2023 | -4.48 Mn |
| Sep 30, 2023 | 8.89 Mn |
| Sep 30, 2023 | 8.89 Mn |
| Jun 30, 2023 | -5.71 Mn |
| Jun 30, 2023 | -5.71 Mn |
| Mar 31, 2023 | 1.77 Mn |
| Mar 31, 2023 | 1.77 Mn |
| Dec 31, 2022 | 2.45 Mn |
| Dec 31, 2022 | 2.45 Mn |
| Sep 30, 2022 | -3.06 Mn |
| Sep 30, 2022 | -3.06 Mn |
| Jun 30, 2022 | 3.56 Mn |
| Jun 30, 2022 | 3.56 Mn |
| Mar 31, 2022 | 1.55 Mn |
| Mar 31, 2022 | 1.55 Mn |
| Dec 31, 2021 | -330,000.00 |
| Dec 31, 2021 | -330,000.00 |
| Sep 30, 2021 | -2.18 Mn |
| Sep 30, 2021 | -2.18 Mn |
| Jun 30, 2021 | -1.54 Mn |
| Jun 30, 2021 | -1.54 Mn |
| Mar 31, 2021 | 7.35 Mn |
| Mar 31, 2021 | 7.35 Mn |
| Dec 31, 2020 | -1.42 Mn |
| Dec 31, 2020 | -1.42 Mn |
| Sep 30, 2020 | -320,000.00 |
| Sep 30, 2020 | -320,000.00 |
| Jun 30, 2020 | -242,000.00 |
| Jun 30, 2020 | -242,000.00 |
| Mar 31, 2020 | -1.76 Mn |
| Mar 31, 2020 | -1.76 Mn |
| Dec 31, 2019 | 3.07 Mn |
| Dec 31, 2019 | 3.07 Mn |
| Sep 30, 2019 | -567,000.00 |
| Sep 30, 2019 | -567,000.00 |